Citation Impact
Citing Papers
Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer
2008 Standout
mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt
2006 Standout
Activity of SU11248, a Multitargeted Inhibitor of Vascular Endothelial Growth Factor Receptor and Platelet-Derived Growth Factor Receptor, in Patients With Metastatic Renal Cell Carcinoma
2005 Standout
MK-2206, an Allosteric Akt Inhibitor, Enhances Antitumor Efficacy by Standard Chemotherapeutic Agents or Molecular Targeted Drugs In vitro and In vivo
2010 Standout
Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
2008 Standout
Molecular Mechanism of Antibody-Mediated Activation of β-galactosidase
2014 StandoutNobel
Treatment of kidney cancer
2009 StandoutNobel
Hallmarks of Cancer: The Next Generation
2011 Standout
Improving the outcome of patients with castration-resistant prostate cancer through rational drug development
2006
Molecular imaging in drug development
2008 Standout
Acromegaly
2006 Standout
Functional responses and in vivo anti-tumour activity of h7C10: A humanised monoclonal antibody with neutralising activity against the insulin-like growth factor-1 (IGF-1) receptor and insulin/IGF-1 hybrid receptors
2007
IGF-I mediated survival pathways in normal and malignant cells
2006
Patient-Derived Xenograft Models: An Emerging Platform for Translational Cancer Research
2014 Standout
The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism
2006 Standout
The MET receptor tyrosine kinase in invasion and metastasis
2007
Insulin-Like Growth Factor (IGF) family and prostate cancer
2006
Insulin-like growth factors and neoplasia
2004
New Insights into the Biology of Renal Cell Carcinoma
2011 StandoutNobel
IGF1 and IGFBP3 tagging polymorphisms are associated with circulating levels of IGF1, IGFBP3 and risk of breast cancer
2005
Survey of the year 2004 commercial optical biosensor literature
2005
Epidemiology of Prostate Cancer
2019 Standout
Mendelian randomization: Using genes as instruments for making causal inferences in epidemiology
2007 Standout
Phage-encoded combinatorial chemical libraries based on bicyclic peptides
2009 StandoutNobel
Targeting the phosphoinositide 3-kinase pathway in cancer
2009 Standout
MicroRNAs as Regulators, Biomarkers and Therapeutic Targets in the Drug Resistance of Colorectal Cancer
2016
Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
2011 Standout
Engineered antibody fragments and the rise of single domains
2005
Insulin and insulin-like growth factor signalling in neoplasia
2008 Standout
Fibroblast growth factor signalling: from development to cancer
2010 Standout
Blocking the insulin-like growth factor-I receptor as a strategy for targeting cancer
2005
Vascular endothelial growth factor in eye disease
2008 Standout
Cancer as an overhealing wound: an old hypothesis revisited
2008 Standout
mTOR: from growth signal integration to cancer, diabetes and ageing
2010 Standout
Small-molecule inhibitors of protein–protein interactions: progressing towards the dream
2004 Standout
Molecular requirements for epithelial–mesenchymal transition during tumor progression
2005 Standout
PTEN hamartoma tumor syndromes
2008 Standout
The VHL/HIF axis in clear cell renal carcinoma
2012 StandoutNobel
Molecular genetics in acute myeloid leukemia
2010
Prolonged Rapamycin Treatment Inhibits mTORC2 Assembly and Akt/PKB
2006 Standout
The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth
2023 Standout
Insulin receptor (IR) and insulin-like growth factor receptor 1 (IGF-1R) signaling systems: novel treatment strategies for cancer
2013
Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
2013 Standout
Survey of the year 2003 commercial optical biosensor literature
2004
The growth hormone receptor antagonist pegvisomant blocks both mammary gland development and MCF-7 breast cancer xenograft growth
2006
Pancreatic Cancer
2010 Standout
Tumor metastasis: mechanistic insights and clinical challenges
2006 Standout
Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer
2008 Standout
Activation of RON differentially regulates claudin expression and localization: role of claudin-1 in RON-mediated epithelial cell motility
2007
Monoclonal antibody antagonists of hypothalamic FGFR1 cause potent but reversible hypophagia and weight loss in rodents and monkeys
2006
Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study
2011 Standout
Development of therapeutic antibodies for the treatment of diseases
2020 Standout
The PI3K Pathway in Human Disease
2017 Standout
Ras, PI(3)K and mTOR signalling controls tumour cell growth
2006 StandoutNature
Targeting PI3K signalling in cancer: opportunities, challenges and limitations
2009 Standout
Modes of resistance to anti-angiogenic therapy
2008 Standout
Tumor Angiogenesis
2008 Standout
Insulin-Like Growth Factor 1 Receptor Targeted Therapeutics: Novel Compounds and Novel Treatment Strategies for Cancer Medicine
2008
Natural polyphenols: An overview
2016 Standout
Electrochemical Biosensors - Sensor Principles and Architectures
2008 Standout
IMC-A12, a Human IgG1 Monoclonal Antibody to the Insulin-Like Growth Factor I Receptor
2007
New Approaches to Immunotherapy for HPV Associated Cancers
2011
Growth factor receptors and related signalling pathways as targets for novel treatment strategies of hepatocellular cancer
2008
Ramucirumab for the treatment of gastric cancers, colorectal adenocarcinomas, and other gastrointestinal malignancies
2016
Phase I, Pharmacokinetic and Pharmacodynamic Study of the Anti–Insulinlike Growth Factor Type 1 Receptor Monoclonal Antibody CP-751,871 in Patients With Multiple Myeloma
2008
Blockade of Paracrine Supply of Insulin-Like Growth Factors Using Neutralizing Antibodies Suppresses the Liver Metastasis of Human Colorectal Cancers
2005
An Antibody Targeting the Type I Insulin-like Growth Factor Receptor Enhances the Castration-Induced Response in Androgen-Dependent Prostate Cancer
2007
Increased Plasma Vascular Endothelial Growth Factor (VEGF) as a Surrogate Marker for Optimal Therapeutic Dosing of VEGF Receptor-2 Monoclonal Antibodies
2004
Combination therapy in combating cancer
2017 Standout
Contributions of Amino Acid Side Chains to the Kinetics and Thermodynamics of the Bivalent Binding of Protein L to Ig κ Light Chain
2004 StandoutNobel
Unique potential of 4-1BB agonist antibody to promote durable regression of HPV + tumors when combined with an E6/E7 peptide vaccine
2015 StandoutNobel
The Versatile Role of microRNA-30a in Human Cancer
2017 Standout
Surface Plasmon Resonance Sensors for Detection of Chemical and Biological Species
2008 Standout
Claudins and the Modulation of Tight Junction Permeability
2013 Standout
Disrupting insulin-like growth factor signaling as a potential cancer therapy
2007
Vascular Endothelial Growth Factor Stimulates Organ-Specific Host Matrix Metalloproteinase-9 Expression and Ovarian Cancer Invasion
2008
Inhibition of insulin-like growth factor-I receptor (IGF-IR) signaling and tumor cell growth by a fully human neutralizing anti–IGF-IR antibody
2005
Lymphatic vessels in cancer
2022
Nanobodies: Natural Single-Domain Antibodies
2013 Standout
Combination Therapy Enhances the Inhibition of Tumor Growth with the Fully Human Anti–Type 1 Insulin-Like Growth Factor Receptor Monoclonal Antibody CP-751,871
2005
Phage display-derived human antibodies in clinical development and therapy
2016
Works of Dan Lu being referenced
Therapeutic Implications of a Human Neutralizing Antibody to the Macrophage-Stimulating Protein Receptor Tyrosine Kinase (RON), a c-MET Family Member
2006
Potent neutralization of VEGF biological activities with a fully human antibody Fab fragment directed against VEGF receptor 2
2006
Treatment with demethylating agent, 5-aza-2′-deoxycytidine enhances therapeutic HPV DNA vaccine potency
2009
A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo.
2003
A recombinant, fully human, bispecific antibody neutralizes the biological activities mediated by both vascular endothelial growth factor receptors 2 and 3
2005
Suppression of leukemia expressing wild-type or ITD-mutant FLT3 receptor by a fully human anti-FLT3 neutralizing antibody
2004